Abstract
Introduction
3-Hydroxy-3-methyl-glutaryl Co-A reductase inhibitors (HMG Co-A reductase inhibitors, statins) are commonly used medications for the control of serum cholesterol. Recent data suggests that these medications also modify the inflammatory pathways in sepsis, septic shock, and hemorrhagic shock due to ruptured abdominal aortic aneurysms. Statin use in hemorrhagic shock due to trauma, however, has conflicting data, with one study showing improvement, but only in certain subsets of patients.
Study design
We retrospectively reviewed the medical records of patients from our institution’s trauma registry database from January 2000 to December 2008. We included patients with an age greater than 45 years and an Injury Severity Score (ISS) greater than 15 with evidence of shock as follows: hypotension, elevated serum lactate, base deficit, metabolic acidosis, or objective evidence of end-organ malperfusion. We excluded patients with devastating head injury, patients with pre-existing advance directives directing against life-sustaining measures, patients for whom family or health care proxies withdrew support in 24 h or less, and patients who succumbed to their injuries in the first 24 h in the hospital. We compared age, gender, mortality, statin use, aspirin use, and Sequential Organ Failure Assessment (SOFA) scores.
Results
Mortality in the group without prehospital statin use was 38.1% (95% confidence interval [CI]: 28.4–48.8%) and mortality in the group with prehospital statin use was 8.3% (95% CI: 2.13–22.5%, P = 0.0009). The absolute risk reduction was 29.8% and the relative risk reduction was 78.1%. Survivors were statistically significantly younger than nonsurvivors in the group without prehospital statin use, but not in the group with documented prehospital statin use. There was no similar benefit to aspirin use. There were no significant differences in the SOFA scores, hospital length of stay (HLOS), or intensive care unit length of stay (ICU LOS) between statin users and nonusers.
Conclusions
Prehospital HMG Co-A reductase use was associated with improved survival in a population with severe trauma and evidence of ongoing hemorrhagic shock.
Similar content being viewed by others
References
Chen CH, Lee RP, Wu WT, Liao KW, Hsu N, Hsu BG. Fluvastatin ameliorates endotoxin induced multiple organ failure in conscious rats. Resuscitation. 2007;74(1):166–74.
Acheampong E, Parveen Z, Mengistu A, Ngoubilly N, Wigdahl B, Lossinsky AS, Pomerantz RJ, Mukhtar M. Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro. J Virol. 2007;81(3):1492–501.
Chua D, Tsang RS, Kuo IF. The role of statin therapy in sepsis. Ann Pharmacother. 2007;41(4):647–52.
Pirillo A, Jacoviello C, Longoni C, Radaelli A, Catapano AL. Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells. Biochem Biophys Res Commun. 1997;231(2):437–41.
Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001;21:115–21.
Murata T, Kinoshita K, Hori M, Kuwahara M, Tsubone H, Karaki H, Ozaki H. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2005;25(11):2335–42.
Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, Antunes-Rodrigues J. Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. Shock. 2004;21(3):271–5.
Uchiyama T, Atsuta H, Utsugi T, Ohyama Y, Nakamura T, Nakai A, Nakata M, Maruyama I, Tomura H, Okajima F, Tomono S, Kawazu S, Nagai R, Kurarbayashi M. Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006;188(2):265–73.
Wei CY, Huang KC, Chou YH, Hsieh PF, Lin KH, Lin WW. The role of Rho-associated kinase in differential regulation by statins of interleukin-1beta- and lipopolysaccharide-mediated nuclear factor kappaB activation and inducible nitric-oxide synthase gene expression in vascular smooth muscle cells. Mol Pharmacol. 2006;69(3):960–7.
Schmidt H, Hennen R, Keller A, Russ M, Müller-Werdan U, Werdan K, Buerke M. Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome. Intensive Care Med. 2006;32(8):1248–51.
Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110:880–5.
Efron DT, Sorock G, Haut ER, Chang D, Schneider E, Mackenzie E, Cornwell EE 3rd, Jurkovich GJ. Preinjury statin use is associated with improved in-hospital survival in elderly trauma patients. J Trauma. 2008;64(1):66–73.
Feeney JM, Burns KA, Staff I, Bai JA, Rodrigues N, Fortier J, Jacobs LM. Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm. J Am Coll Surg. 2009;209:41–6.
Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest. 2003;124(2):740–3.
Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006;37(7):1923–32.
Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int. 2006;69(9):1535–42.
Efthymiou CA, Mocanu MM, Yellon DM. Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. J Cardiovasc Pharmacol. 2005;45(3):247–52.
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Feeney, J.M., Jayaraman, V., Spilka, J. et al. Prehospital HMG Co-A reductase inhibitor use and reduced mortality in hemorrhagic shock due to trauma. Eur J Trauma Emerg Surg 38, 171–176 (2012). https://doi.org/10.1007/s00068-011-0144-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00068-011-0144-z